SCHEMBL2205376

SCHEMBL2205376

CC(C)(C)OC(=O)NC1CCc2n[nH]cc2C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
CTSK P43235 2/20 0.41
BTK Q06187 3/20 0.41
DRD2 P14416 3/20 0.40
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
GAA P10253 1/20 0.40
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
JAK3 P52333 1/20 0.38
KCNA3 P22001 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27477375 0.88 EPHX2 (0.50) EPHX2CTSKBTKDRD2JAK2
SCHEMBL11211906 0.83 MTNR1A (0.54) MTNR1AMTNR1B
SCHEMBL11232532 0.80 MTNR1A (0.57) GAAKMT2AL3MBTL1MTNR1AMTNR1B
SCHEMBL11212845 0.79 MTNR1A (0.49) MTNR1AMTNR1B
SCHEMBL25934498 0.77 EPHX2 (0.45) EPHX2CTSKBTKDRD2KDM1A
SCHEMBL2827001 0.75 EPHX2 (0.46) EPHX2CTSKBTKDRD2JAK2
SCHEMBL31564729 0.75 EPHX2 (0.48) EPHX2CTSKBTKDRD2GAA
SCHEMBL29565539 0.75 MTNR1A (0.66) EPHX2BTKDRD2KDM1AMAOB
SCHEMBL3682479 0.75 MTNR1A (0.66) EPHX2BTKDRD2KDM1AMAOB
SCHEMBL31564530 0.75 EPHX2 (0.48) EPHX2CTSKBTKDRD2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 US disclosed
EP-2029579-B1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2014-12-31 EP disclosed
US-7981918-B2 Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-30 US disclosed
EP-2029579-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS KCNT1, KCNT2, KCNN3 EPHX2 3911/4885CTSK 3660/4885BTK 3565/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 EPHX2 3219/4885CTSK 4502/4885BTK 2996/4885
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD17B1 EPHX2 1765/4885CTSK 2384/4885BTK 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.